OHV Abrocitinib until 30.04.2028

This tender concerns the offering of discount contracts for the active substance Abrocitinib, valid until April 30, 2028. The contracts are being offered to all suitable and interested pharmaceutical companies or consortia of pharmaceutical companies. The objective is to establish uniform contract conditions and a standardized access procedure for these agreements, as stipulated by § 130a Abs. 8 SGB V (German Social Code Book V). The earliest possible start date for these contracts is May 1, 2026. The maximum contract duration will be 24 months from this start date. This initiative aims to secure the supply of Abrocitinib under favorable terms for the contracting party, likely a statutory health insurance fund or a similar public entity in Germany. Pharmaceutical companies interested in supplying Abrocitinib within this framework are invited to submit proposals that align with the specified conditions. The focus is on negotiating discount agreements to ensure cost-effective procurement of this specific pharmaceutical product.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals and Health Financing. Located in Germany, Europe, this opportunity is open to firms and consortiums. Proposals must be submitted before March 27, 2028.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. Interested parties should review the full documentation on the original source before submitting their proposal.